Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638128 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT03638128 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 75 participants.
The verdict
NCT03638128, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
Interventions
- DRUG Denosumab
- DRUG Alternative osteoporosis medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03638128
The ClinicalTrials.gov registry entry for NCT03638128 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Denosumab is the first listed.
NCT03638128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03638128 about?
NCT03638128 is a clinical study titled "Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta". To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
What is the current status of trial NCT03638128?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2018-07-26. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT03638128?
The interventions under investigation include: Denosumab (DRUG), Alternative osteoporosis medications (DRUG).
Who is sponsoring clinical trial NCT03638128?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.